Navigation Links
USC researchers identify novel approach for suppressing prostate cancer development
Date:11/24/2008

Los Angeles, Calif. Nov. 24, 2008Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models.

Researchers say the upcoming study in the Proceedings of the National Academy of Sciencesnow available onlinemay lead to a novel cancer therapy for humans.

"This research has far-reaching implications in a wide range for human cancers," says Amy Lee, Ph.D., the study's principal investigator and the associate director for basic research and holder of the Freeman Cosmetics Chair at the USC/Norris Comprehensive Cancer Center, and professor of biochemistry and molecular biology at the Keck School of Medicine of USC. "It is a breakthrough study."

Prostate cancer is the most common cancer in men and develops through successive stages. The glucose-regulated protein GRP78 has been identified as a crucial entity in the development of prostate cancer by promoting cancer cell proliferation, mediating oncogenic signaling and protecting cancer cells against cell death resulting from the stress of tumor development, Lee explains. By suppressing GRP78 expression or activity, the USC researchers found that they could block prostate cancer activation and development resulting from the loss of PTEN, a powerful tumor suppressor gene for a number of human cancers.

Researchers spent more than three years monitoring prostate cancer development in animal models that had been genetically engineered to have both the GRP78 and PTEN tumor suppressor genes inactivated. The research was conducted by Yong Fu, a Ph.D. candidate at the Keck School of Medicine of USC and the first author on the study, in collaboration with Ph.D candidates Shiuan Wey, Miao Wang, Risheng Ye and Chun-Peng Liao and Pradip Roy-Burman, M.D., professor of pathology, biochemistry and molecular biology at the Keck School.

Future research should test the role of GRP78 in other types of cancer and isolate drugs that inhibit GRP78, Lee says. "To our knowledge, this is the first demonstration that inactivation of a specific molecular chaperone from the mouse prostate epithelial cells can potently block prostate cancer development and suppress the activation of AKT, which is a protein kinase that promotes cell proliferation and survival and is a major factor in many types of cancer," Lee says. "With the recent advances in identifying agents that suppress GRP78 expression, anti-GRP78 therapy may open up an entirely new approach to stop human cancer."


'/>"/>

Contact: Meghan Lewit
lewit@usc.edu
323-442-3941
University of Southern California
Source:Eurekalert

Related medicine news :

1. Researchers identify new leprosy bacterium
2. UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
3. Researchers discover strategy for predicting the immunity of vaccines
4. Ability to quit smoking may depend on ADHD symptoms, Columbia researchers find
5. Researchers ID Suite of Genes in Aging Process
6. Researchers: Ban on fast food TV advertising would reverse childhood obesity trends
7. Brigham and Womens Researchers Partner with Vocantas to use CallAssure in Clinical Research Study
8. Leeds researchers reshape the future of drug discovery
9. UNC researchers find clue to stopping breast-cancer metastasis
10. U of U researchers to use patients own stem cells to treat heart failure
11. Researchers identify toehold for HIVs assault on brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
Breaking Medicine Technology: